Innovent Biologics announces overall survival results from phase two pemigatinib study in Chinese subjects with advanced cholangiocarcinoma
Saved in:
| Published in | M2 Pharma |
|---|---|
| Format | Newsletter |
| Language | English |
| Published |
London
Normans Media Ltd
20.04.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Description not available. |